9 November 2026 at 10:00 UTC, as stated in the official notice.
10:00 AM · UTC
Contract value
Not stated in the notice
Contract period
Two years, then continues indefinitely until terminated
Published
October 8, 2026
Hilma / Finnish public eForms notice
Overview
HUSLAB, the genetics laboratory at Helsinki University Hospital, seeks an MLPA assay for detecting copy-number variations in BRCA1 and BRCA2. The supply must include reagents, controls, consumables, software, licences, user rights, technical support and services needed for routine testing, analysis and reporting. Estimated annual use is about 1,600 reportable samples, expressly non-binding. The agreement runs for two years and then continues indefinitely until terminated. Offers in Finnish or English are due 9 November 2026 at 10:00 UTC; the lowest total comparison price is the award criterion.
Supply of a complete MLPA-based genetic testing assay for BRCA1 and BRCA2 CNV detection, including the software, consumables and support required for operational use and reporting.
Tenders may be submitted in Finnish or English. Partial, parallel and alternative tenders are not accepted.
The contracting authority requires electronic tender submission.
Lots
LOT-0000 ·MLPA-Based CNV Testing for BRCA1/BRCA2
Tender details
Buyer
HUS Group, the joint authority for Helsinki and Uusimaa
Country
Finland
Procedure
open
Classification
Genetic testing supplies · CPV 33696500 33000000
Notice reference
EF-58857
Test method
MLPA assay for BRCA1/BRCA2 copy-number variations
Estimated annual use
Approximately 1,600 reportable samples; non-binding estimate
Contract period
Two years, then continues indefinitely until terminated
What to check in the tender documents
Annual sample volume is indicative and non-binding; actual purchases depend on the buyer’s needs. No estimated monetary value is stated.
2026-058857 — MLPA-Based CNV Testing for BRCA1/BRCA2
HUSLAB Laboratory of Genetics at HUS (Helsinki University Hospital) Diagnostic Center is an SFS-EN ISO 15189:2022 accredited laboratory providing diagnostic and follow-up genetic testing services for patients within the Helsinki University Hospital area.
The object of the procurement is an MLPA (Multiplex Ligation-dependent Probe Amplification) assay for the detection of copy number variations (CNVs) in BRCA1 and BRCA2 genes, including all reagents, controls, consumables, software, licences and other components required for routine use of the assay and generation of reportable patient results.
The procurement also includes any software, licences, user rights, technical support and related services required for operation of the assay, data analysis and result reporting
The contract period shall be two (2) years, after which the agreement shall continue for an indefinite period until terminated in accordance with the terms of the agreement.
The estimated annual consumption is approximately 1600 reportable patient samples.
The estimate is non-binding and provided for information purposes only. The contracting entity does not commit to any specific purchase volumes or quantities. Actual purchases will be made based on the contracting entity's needs and may be higher or lower than estimated.
The contract period shall be two (2) years, after which the agreement shall continue for an indefinite period until terminated in accordance with the terms of the agreement.
The Customer reserves the right during the contract period to add products belonging to the product group covered by the contract and consistent with the nature, purpose and scope of the procurement. Such additions may concern new or previously unidentified products within the product group and shall be subject to the terms and conditions of the contract.
The procurement shall comply with the Act on Public Procurement and Concession Contracts (1397/2016, referred to as the Public Procurement Act). The procurement value exceeds the EU threshold value. The procedure shall be an open procedure as defined in section 32 of the Public Procurement Act.
The procedure shall include the following phases:
Contracting entity
1. Opens the tenders
2. Verifies the suitability of the tenderer
3. Checks that the tenders conform to the invitation to tender
4. Compares the tenders
5. Requests and checks certificates and reports on the suitability of the winning tenderer(s)
6. Makes a procurement decision and communicates it to all the tenderers
7. Concludes an agreement with the selected tenderer(s)
LANGUAGE OF THE COMPETITIVE TENDERING PROCEDURE
Tenders may be submitted in either Finnish or English. Product brochures, technical documentation and other supporting materials may also be provided in either Finnish or English.
PARTIAL TENDERS
Partial tenders will not be accepted.
PARALLEL TENDERS
Parallel tenders are not permitted.
ALTERNATIVE TENDERS
Alternative tenders will not be accepted.